Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1SLC9A3
The experimentally established mechanism targets of L-Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA4 | P22748 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Lactic Acid SCHEMBL29683337 | 1.00 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL3411524 | 1.00 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL29484432 | 1.00 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL29974371 | 1.00 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL676986 | 1.00 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL29683364 | 1.00 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL28775524 | 0.97 | TP53 (0.44) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL22341771 | 0.96 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL29386349 | 0.96 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL25193 | 0.96 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140121273-A1 | METHOD FOR TREATMENT OF MAGNESIUM AND POTASSIUM DEFICIENCIES | PHARMALYTE SOLUTIONS, LLC (US) | 2014-05-01 | — | — | US | claimed |
| WO-2006121943-A2 | METHOD FOR THE TREATMENT OF MAGNESIUM AND POTASSIUM DEFICIENCIES | NICHE PHARMACEUTICALS, INC. (US) | 2006-11-16 | — | — | WO | claimed |
| US-20260137715-A1 | AQUEOUS FORMULATION INCLUDING DISSOLVED HYDROGEN GAS AND MINERALS AND ADDITIVES | BEST PLANET SCIENCE LLC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4736977-A2 | CRYSTALLIZATION OF HIGH-PURITY MAGNESIUM L-LACTATE | TripleW Ltd. (IL) | 2026-05-06 | — | — | EP | disclosed |
| EP-4281432-B1 | CRYSTALLIZATION OF HIGH-PURITY MAGNESIUM L-LACTATE | TRIPLEW LTD (IL) | 2026-03-11 | — | — | EP | disclosed |
| US-12558373-B1 | Method for converting atrial fibrillation to sinus rhythm with low-risk, low-cost protocol, and preventing recurrence of atrial fibrillation | WANDERER ALAN (US) | 2026-02-24 | — | — | US | disclosed |
| US-12527815-B2 | Aqueous formulation including dissolved hydrogen gas and minerals and additives | BEST PLANET SCIENCE LLC (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250072457-A1 | Beverages Comprising Protein Sweeteners with Improved Taste and Mouthfeel | THE COCA-COLA COMPANY | 2025-03-06 | — | — | US | disclosed |
| US-20250031742-A1 | GEL-LIKE FOOD SUPPLEMENT COMPOSITION | TECHTURE OÜ (EE) | 2025-01-30 | — | — | US | disclosed |
| CN-119330822-A | Crystallization of high purity L-magnesium lactate | 三W有限公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-4456739-A1 | BEVERAGES COMPRISING PROTEIN SWEETENERS WITH IMPROVED TASTE AND MOUTHFEEL | The Coca-Cola Company (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-101018756-A | Process for the preparation of lactic acid or lactate from a magnesium lactate comprising medium | PURAC BIOCHEM BV (NL) | 2007-08-15 | — | — | CN | disclosed |
| WO-2007075255-A2 | MASTIC GUM COMPOSITION FOR USE AS A DIETARY SUPPLEMENT IN HUMANS AND ANIMALS | INTACT ENTERPRISES, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070148187-A1 | MASTIC GUM COMPOSITION FOR USE AS A DIETARY SUPPLEMENT IN HUMANS AND ANIMALS | INTACT ENTERPRISES, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| EP-1765757-A1 | PROCESS FOR THE PREPARATION OF LACTIC ACID OR LACTATE FROM A MAGNESIUM LACTATE COMPRISING MEDIUM | PURAC Biochem BV (NL) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006121943-A2 | METHOD FOR THE TREATMENT OF MAGNESIUM AND POTASSIUM DEFICIENCIES | NICHE PHARMACEUTICALS, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| EP-1696937-A1 | PREBIOTIC COMBINATION PRODUCTS | Nova Biotics AS (NO) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005123647-A1 | PROCESS FOR THE PREPARATION OF LACTIC ACID OR LACTATE FROM A MAGNESIUM LACTATE COMPRISING MEDIUM | PURAC BIOCHEM B.V. (NL) | 2005-12-29 | — | — | WO | disclosed |
| US-20050281913-A1 | Process for the preparation of lactic acid or lactate from a magnesium lactate comprising medium | PURAC BIOCHEM BV (NL) | 2005-12-22 | — | — | US | disclosed |
| WO-2005056023-A1 | PREBIOTIC COMBINATION PRODUCTS | NOVA BIOTICS AS (NO) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558373-B1 | Method for converting atrial fibrillation to sinus rhythm with low-risk, low-cost protocol, and preventing recurrence of atrial fibrillation | KCNH1, ATP2A1, ATP2A3 | TP53 4534/4885CA1 1112/4885CA4 1478/4885 |
| US-20260137715-A1 | AQUEOUS FORMULATION INCLUDING DISSOLVED HYDROGEN GAS AND MINERALS AND ADDITIVES | SDHB, ABCB7, SLC9B2 | TP53 1802/4885CA1 10/4885CA4 361/4885 |
| US-12527815-B2 | Aqueous formulation including dissolved hydrogen gas and minerals and additives | SLC7A11, SDHB, LDHB | TP53 980/4885CA1 53/4885CA4 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.